News
Public · Published
Pfizer's Revenue Barely Moved. Its Forecast Just Went Higher
Pfizer raised its 2026 revenue forecast to $62 billion to $64 billion, from $60.5 billion to $62.5 billion, after third-quarter revenue of $16.6 billion beat expectations by about $700 million, despite falling COVID-19 product sales.
Published:
Updated:
What happened
Pfizer raised its 2026 revenue forecast to $62 billion to $64 billion, from $60.5 billion to $62.5 billion, after third-quarter revenue of $16.6 billion beat expectations by about $700 million, despite falling COVID-19 product sales.
Confirmed
Global impact / market context
The raised forecast signals that Pfizer expects newer products and cancer treatments to replace shrinking COVID-19 revenue. This matters because it shows the company is reshaping its business, which can affect future profits, cash available, and how investors value the stock.
Analyst inference
Pfizer's mixed results reflect a sector-wide shift: COVID-19 sales are falling, but cancer and blood thinner drugs are growing. Investors are watching whether drugmakers can replace fading pandemic revenue with new products, while also tracking costs and management changes.
Analyst inference
What to watch
- Watch whether sales of Eliquis and Padcev continue growing at 25% and 55% respectively, as these products are key to offsetting declining COVID-19 revenue. Confirmed
- Pfizer may need to increase spending on research and new products to sustain growth, which could pressure profit per sale if costs rise faster than revenue. Proposed
- If COVID-19 sales keep falling, Pfizer's ability to meet its raised forecast depends on newer products and cancer treatments, affecting investor confidence and stock performance. Analyst inference